vs
Side-by-side financial comparison of OmniAb, Inc. (OABI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $8.4M, roughly 1.6× OmniAb, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -169.3%, a 245.0% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-5.7M).
OmniAb, Inc. is a global biotechnology firm specializing in proprietary transgenic animal platforms and antibody discovery solutions. It partners with pharma and biotech clients to accelerate fully human therapeutic antibody development for oncology, autoimmune diseases and high-need medical areas across key global markets.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
OABI vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.4M | $13.7M |
| Net Profit | $-14.2M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | -188.2% | -86.5% |
| Net Margin | -169.3% | 75.7% |
| Revenue YoY | -22.5% | — |
| Net Profit YoY | -8.5% | 179.1% |
| EPS (diluted) | $-0.11 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.4M | $13.7M | ||
| Q3 25 | — | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $10.8M | — | ||
| Q2 24 | $7.6M | — | ||
| Q4 23 | $4.8M | — | ||
| Q3 23 | $5.5M | — |
| Q4 25 | $-14.2M | $10.4M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-13.3M | ||
| Q4 24 | $-13.1M | — | ||
| Q2 24 | $-13.6M | — | ||
| Q4 23 | $-14.1M | — | ||
| Q3 23 | $-15.7M | — |
| Q4 25 | -188.2% | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q4 24 | -147.0% | — | ||
| Q2 24 | -214.1% | — | ||
| Q4 23 | -439.8% | — | ||
| Q3 23 | -370.9% | — |
| Q4 25 | -169.3% | 75.7% | ||
| Q3 25 | — | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | — | -452.7% | ||
| Q4 24 | -121.0% | — | ||
| Q2 24 | -179.0% | — | ||
| Q4 23 | -291.4% | — | ||
| Q3 23 | -287.3% | — |
| Q4 25 | $-0.11 | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | $-0.13 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q4 23 | $-0.14 | — | ||
| Q3 23 | $-0.16 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $267.0M | $35.3M |
| Total Assets | $300.9M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.5M | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | $27.6M | — | ||
| Q2 24 | $20.8M | — | ||
| Q4 23 | $16.4M | — | ||
| Q3 23 | $21.2M | — |
| Q4 25 | $267.0M | $35.3M | ||
| Q3 25 | — | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $10.7M | ||
| Q4 24 | $287.6M | — | ||
| Q2 24 | $294.2M | — | ||
| Q4 23 | $314.6M | — | ||
| Q3 23 | $324.5M | — |
| Q4 25 | $300.9M | $154.7M | ||
| Q3 25 | — | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | $325.6M | — | ||
| Q2 24 | $337.3M | — | ||
| Q4 23 | $375.2M | — | ||
| Q3 23 | $391.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.7M | $-2.0M |
| Free Cash FlowOCF − Capex | $-5.7M | $-2.1M |
| FCF MarginFCF / Revenue | -67.8% | -15.3% |
| Capex IntensityCapex / Revenue | 0.1% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-31.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.7M | $-2.0M | ||
| Q3 25 | — | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | $-3.9M | — | ||
| Q2 24 | $-12.2M | — | ||
| Q4 23 | $-9.1M | — | ||
| Q3 23 | $-6.2M | — |
| Q4 25 | $-5.7M | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | $-3.9M | — | ||
| Q2 24 | $-12.9M | — | ||
| Q4 23 | $-9.2M | — | ||
| Q3 23 | $-6.7M | — |
| Q4 25 | -67.8% | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | -36.3% | — | ||
| Q2 24 | -169.9% | — | ||
| Q4 23 | -191.4% | — | ||
| Q3 23 | -122.1% | — |
| Q4 25 | 0.1% | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 0.4% | — | ||
| Q2 24 | 9.9% | — | ||
| Q4 23 | 2.2% | — | ||
| Q3 23 | 8.9% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
